O
Otto Visser
Researcher at VU University Medical Center
Publications - 264
Citations - 18801
Otto Visser is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Population & Cancer. The author has an hindex of 53, co-authored 240 publications receiving 14262 citations. Previous affiliations of Otto Visser include Utrecht University & University Medical Center Groningen.
Papers
More filters
Journal ArticleDOI
Variation between hospitals in surgical margins after first breast-conserving surgery in the Netherlands
Margriet van der Heiden-van der Loo,Linda de Munck,Otto Visser,Pieter J. Westenend,Thijs van Dalen,M. B. Menke,Emiel J. Th. Rutgers,Petra H.M. Peeters +7 more
TL;DR: In this paper, the authors describe the variation in surgical margin status between hospitals in the Netherlands and present funnel plots to compare the performance of different hospitals in terms of the percentage of positive margins.
Journal ArticleDOI
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.
Martine E.D. Chamuleau,Coreline N. Burggraaff,Marcel Nijland,Katerina Bakunina,Rogier Mous,Pieternella J. Lugtenburg,Daan Dierickx,Gustaaf W. van Imhoff,Joost Vermaat,Eric A. F. Marijt,Otto Visser,Caroline M.P.W. Mandigers,Yavuz M. Bilgin,Aart Beeker,Mark F. Durian,Bas P. van Rees,Lara H Böhmer,Lidwine W. Tick,Rinske S. Boersma,Tjeerd J. F. Snijders,Harry C. Schouten,Harry R. Koene,Eva de Jongh,Nathalie J. Hijmering,Arjan Diepstra,Anke van de Berg,Anne I.J. Arens,J. E. Huijbregts,Otto S. Hoekstra,Josée M. Zijlstra,Daphne de Jong,Marie José Kersten +31 more
TL;DR: It is found that administering R2CHOP was safe, and yields comparable CMR and survival rates as in studies applying more intensive chemotherapy regimens, which offer new prospects for MYC+ LBCL patients and warrant comparison in prospective randomized clinical trials.
Journal ArticleDOI
Improvement of Care in Patients With Colorectal Cancer: Influence of the Introduction of Standardized Structured Reporting for Pathology.
Caro E. Sluijter,Frans van Workum,Theo Wiggers,Carlijn van de Water,Otto Visser,Henk-Jan van Slooten,Lucy I H Overbeek,Iris D. Nagtegaal +7 more
TL;DR: It is demonstrated that use of SSR improved patient care in those with CRC by providing more complete reports of higher quality, which had significant effects on the delivery of adjuvant therapy and patient outcomes.
Journal ArticleDOI
Taste alterations and cancer treatment.
TL;DR: Taste is a combination of different sensations: smell, texture, temperature and saliva play an important role in determining the overall flavor of food and the mechanism for taste and smell abnormalities in cancer patients treated with systemic therapies remains unclear.
cardiovascular Morbidity and Mortality After t reatment for Ductal carcinoma in Situ of the Breast
Naomi B. Boekel,Michael Schaapveld,Jourik A. Gietema,Emiel J. Th. Rutgers,Michel I.M. Versteegh,Otto Visser,B.M.P. Aleman,Flora E. van Leeuwen +7 more
TL;DR: In this paper, the authors found that 5-year survivors of DCIS had a similar risk of dying due to any cause (standardized mortality ratio [SMR] = 1.04; 95% confidence interval [CI] = 0.97 to 1.11) but a lower risk for dying of CVD (SMR = ǫ 0.67 to 0.89).